Vitro Diagnostics Inc. (fka VODG)

[Potse]

Vitropin, wound care, revenue updates.....

Probably a good chance at seeing some type of significant third-party promotion and/or a momentum-assisted move in the share price at some point in calendar 2014. Based on the latest press release and the 10-K filing, the level of corporate/business activity appears to be increasing, and it might start attracting more interest in the coming months.

Vitropin: Although the two parties have decided to keep the Vitropin license agreement active for the time being, it doesn't look like VODG will extract much value from this asset unless an existing player in the space expresses interest in the drug/technology......

During 2011, we completed out-licensing of our patented technology related to FSH manufacture as described elsewhere in this Report. We have a well-established business relationship with the licensee through numerous prior business activities and now also provide the licensee with assistance in sourcing necessary raw materials, distribution of finished product and options to advanced stem-cell based methods for FSH production. The anticipated manufacturing contract with the Contract Manufacturing Organization was not completed in 2013 and there appear to be obstacles to commercialization of Vitropin™. Since many of the primary patents for proprietary FSH drugs have now expired, there a several generic products being introduced to the global market. Many competitors are gaining entry through highly competitive pricing and this is diminishing return on investment capital discouraging further investment.

Wound care product(s): It does appear that some type of joint product development between VODG and James Posillico in the wound care product area may be progressing toward becoming something "official". This is now the first time that VODG has addressed/acknowledged this particular product development in an SEC filing......

However, as described elsewhere, Item 6 of this Report, we are pursuing additional collaboration with our FSH licensee to jointly develop products targeting enhanced wound healing based on novel polymers and known wound healing properties of stem cells.

While it appears that commercialization opportunities for therapeutic FSH are diminishing due to predatory pricing strategies by numerous competitors (See Part I, Item 1), we are developing further opportunities for joint product development with our current FSH patent licensee, Dr. James Posillico. MSCs are known to promote wound healing and through strategic combination of proprietary polymer technology, we are discussing additional collaboration to combine our proprietary stem cell technology and know-how to develop unique wound healing products.

2014 Q1 revenue: Looks like the first quarter revenue will come in over 26K, more than the previous three quarters combined. That would also represent four consecutive quarters of revenue growth. It should be interesting to see if there will be a sequential increase in the second quarter. VODG's expansion into CRO services should provide a more consistently higher level of revenue going forward.....

Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that its revenues increased substantially (78%, unaudited) in its first 2014 fiscal quarter due to its growing and expanding business relationship with Neuromics, Inc. Vitro Biopharma has now commercialized bio-analytical services as the initial stage in its expansion as a Contract Research Organization (CRO). The services now available include select and customized biomarker panel analysis providing customers quantitative levels of multiple biological molecules within various biological samples. The new business involves analysis of human serum samples collected from patients within a network of clinical treatment centers throughout central Europe. Our partner for these services is Joseph Smarta, Ph.D., a renowned immunologist who has orchestrated treatment of many patients suffering from a variety of diseases. While the analyses are for research purposes only, serial analysis of patients are provided to monitor status and indicate therapeutic effectiveness.


Joseph Smarda: Below is an interview Smarda did last week. It primarily focuses on his work with sports figures......

http://www.ibestof.cz/medicina/rndr.-joseph-smarda-bsc.-%E2%80%93-immunologist-biochemist-.html